PT1254138E - Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf - Google Patents
Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegfInfo
- Publication number
- PT1254138E PT1254138E PT01903716T PT01903716T PT1254138E PT 1254138 E PT1254138 E PT 1254138E PT 01903716 T PT01903716 T PT 01903716T PT 01903716 T PT01903716 T PT 01903716T PT 1254138 E PT1254138 E PT 1254138E
- Authority
- PT
- Portugal
- Prior art keywords
- angiogenese
- inhibit
- pyridine derivatives
- tyrosine kinase
- kinase receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH2652000 | 2000-02-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1254138E true PT1254138E (pt) | 2005-09-30 |
Family
ID=4475612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT01903716T PT1254138E (pt) | 2000-02-09 | 2001-02-07 | Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6706731B2 (pt) |
| EP (1) | EP1254138B1 (pt) |
| JP (1) | JP4837864B2 (pt) |
| AT (1) | ATE295365T1 (pt) |
| AU (1) | AU2001231710A1 (pt) |
| DE (1) | DE60110749T2 (pt) |
| ES (1) | ES2241781T3 (pt) |
| HK (1) | HK1052500A1 (pt) |
| PT (1) | PT1254138E (pt) |
| WO (1) | WO2001058899A1 (pt) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200000158A (es) * | 1999-09-28 | 2002-03-16 | Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis. | |
| PT1254138E (pt) * | 2000-02-09 | 2005-09-30 | Novartis Ag | Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf |
| TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| EP1944026B1 (en) * | 2002-05-16 | 2013-06-26 | Novartis AG | Use of EDG receptor binding agents in cancer |
| EP1556053A4 (en) | 2002-10-31 | 2006-04-19 | Amgen Inc | ANTI-INFLAMMATORY AGENTS |
| JP2006519807A (ja) * | 2003-03-11 | 2006-08-31 | ノバルティス アクチエンゲゼルシャフト | 癌およびｍａｐキナーゼ関連疾患の処置のためのイソキノリン誘導体の使用 |
| US7592466B2 (en) | 2003-10-09 | 2009-09-22 | Abbott Laboratories | Ureas having antiangiogenic activity |
| UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| TW200606129A (en) | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
| GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
| EP2134346B1 (en) * | 2007-03-13 | 2011-09-21 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1 |
| BRPI0810123A2 (pt) * | 2007-04-23 | 2014-10-29 | Novartis Ag | Derivados de ftalazina e isoquinolina com atividades moduladoras do receptor de s1p |
| US20110200612A1 (en) | 2008-06-30 | 2011-08-18 | Michael Schuster | Treatment of eye diseases and excessive neovascularization using combined therapy |
| DK2346827T3 (da) | 2008-08-27 | 2014-02-03 | Leo Pharma As | Pyridinderivater som VEGFR-2 receptor og proteintyrosinkinasehæmmere |
| US8592454B2 (en) | 2008-09-19 | 2013-11-26 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound and use of same |
| JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
| AU2010294209A1 (en) | 2009-09-10 | 2012-03-29 | Irm Llc | Ether derivatives of bicyclic heteroaryls |
| WO2011064211A1 (en) | 2009-11-25 | 2011-06-03 | Novartis Ag | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls |
| CN102947275A (zh) | 2010-06-17 | 2013-02-27 | 诺瓦提斯公司 | 哌啶基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物 |
| JP2013528635A (ja) | 2010-06-17 | 2013-07-11 | ノバルティス アーゲー | ビフェニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体 |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| US20130338152A1 (en) | 2011-03-08 | 2013-12-19 | Irm Llc | Fluorophenyl bicyclic heteroaryl compounds |
| PT3176170T (pt) | 2012-06-13 | 2019-02-05 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| KR102469849B1 (ko) | 2013-04-19 | 2022-11-23 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서 이환식 헤테로사이클 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| SG11201706287PA (en) | 2015-02-20 | 2017-09-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| EP3414330A4 (en) | 2016-02-08 | 2019-07-03 | Vitrisa Therapeutics, Inc. | COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF TIME AND USES THEREOF |
| CN110494432B (zh) | 2016-12-28 | 2022-08-12 | 米尼奥尔克斯治疗有限公司 | 异喹啉化合物，其制备方法及其在与β-半乳糖苷酶活性改变相关的病症中的治疗用途 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CA3079076A1 (en) | 2017-10-18 | 2019-04-25 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Methods and compounds for improved immune cell therapy |
| WO2019119486A1 (zh) | 2017-12-21 | 2019-06-27 | 中国科学院合肥物质科学研究院 | 一类嘧啶类衍生物激酶抑制剂 |
| PE20210920A1 (es) | 2018-05-04 | 2021-05-19 | Incyte Corp | Formas solidas de un inhibidor de fgfr y procesos para prepararlas |
| CN112566912A (zh) | 2018-05-04 | 2021-03-26 | 因赛特公司 | Fgfr抑制剂的盐 |
| EP3818046B1 (en) * | 2018-07-02 | 2023-05-10 | Ecole Polytechnique Federale De Lausanne (Epfl) | Lactate enhancing compounds and uses thereof |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TW202128685A (zh) | 2019-10-14 | 2021-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4058465A1 (en) | 2019-11-14 | 2022-09-21 | Cohbar Inc. | Cxcr4 antagonist peptides |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| JP2023533724A (ja) | 2020-07-02 | 2023-08-04 | インサイト・コーポレイション | Ｊａｋ２ ｖ６１７ｆ阻害剤としての三環式尿素化合物 |
| WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| EP4298099A1 (en) | 2021-02-25 | 2024-01-03 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法 |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| AU2023235313A1 (en) | 2022-03-17 | 2024-10-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE792648A (fr) * | 1971-12-13 | 1973-06-12 | May & Baker Ltd | Derives de l'isoquinoleine |
| JPS58164577A (ja) * | 1982-03-24 | 1983-09-29 | Taiho Yakuhin Kogyo Kk | ４―ベンジル―１―（２ｈ）イソキノロン誘導体 |
| US4405790A (en) * | 1982-04-08 | 1983-09-20 | Reilly Tar & Chemical Corp. | Process for preparing 2-alkylamino- and 2-amino-5-alkylpyridines |
| US5679683A (en) * | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| AU2103097A (en) | 1996-03-15 | 1997-10-10 | Zeneca Limited | Cinnoline derivatives and use as medicine |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US6809097B1 (en) * | 1996-09-25 | 2004-10-26 | Zeneca Limited | Quinoline derivatives inhibiting the effect of growth factors such as VEGF |
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| AU5620299A (en) * | 1998-08-11 | 2000-03-06 | Novartis Ag | Isoquinoline derivatives with angiogenesis inhibiting activity |
| PT1254138E (pt) * | 2000-02-09 | 2005-09-30 | Novartis Ag | Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf |
-
2001
- 2001-02-07 PT PT01903716T patent/PT1254138E/pt unknown
- 2001-02-07 EP EP01903716A patent/EP1254138B1/en not_active Expired - Lifetime
- 2001-02-07 AU AU2001231710A patent/AU2001231710A1/en not_active Abandoned
- 2001-02-07 AT AT01903716T patent/ATE295365T1/de active
- 2001-02-07 US US10/203,579 patent/US6706731B2/en not_active Expired - Fee Related
- 2001-02-07 DE DE60110749T patent/DE60110749T2/de not_active Expired - Lifetime
- 2001-02-07 ES ES01903716T patent/ES2241781T3/es not_active Expired - Lifetime
- 2001-02-07 WO PCT/EP2001/001331 patent/WO2001058899A1/en active IP Right Grant
- 2001-02-07 JP JP2001558449A patent/JP4837864B2/ja not_active Expired - Fee Related
-
2003
- 2003-05-06 HK HK03103231A patent/HK1052500A1/xx not_active IP Right Cessation
-
2004
- 2004-01-27 US US10/766,181 patent/US7323474B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20030158409A1 (en) | 2003-08-21 |
| DE60110749T2 (de) | 2006-02-02 |
| WO2001058899A1 (en) | 2001-08-16 |
| US20040209894A1 (en) | 2004-10-21 |
| JP2003522773A (ja) | 2003-07-29 |
| ATE295365T1 (de) | 2005-05-15 |
| AU2001231710A1 (en) | 2001-08-20 |
| US7323474B2 (en) | 2008-01-29 |
| HK1052500A1 (en) | 2003-09-19 |
| US6706731B2 (en) | 2004-03-16 |
| EP1254138A1 (en) | 2002-11-06 |
| EP1254138B1 (en) | 2005-05-11 |
| DE60110749D1 (de) | 2005-06-16 |
| JP4837864B2 (ja) | 2011-12-14 |
| ES2241781T3 (es) | 2005-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1254138E (pt) | Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf | |
| BRPI0113162B8 (pt) | compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos | |
| SE0101675D0 (sv) | Novel composition | |
| NO20061743L (no) | Kinazolinderivater | |
| DE60142921D1 (de) | Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren | |
| PT1274687E (pt) | Derivados de 1,2,3,4-tetra-hidroisoquinolina | |
| BRPI0519759A2 (pt) | composiÇÕes farmacÊuticas | |
| NO20060415L (no) | Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer | |
| ES2243579T3 (es) | Derivados de pirazolopirideno. | |
| BRPI0619153B8 (pt) | derivados de 4-amino-pirroltriazina substituída, e composição farmacêutica | |
| ATE296826T1 (de) | Pyrazolo(1,5)pyridinderivate | |
| NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
| NO20063449L (no) | Substituerte heterocykler og deres anvendelse | |
| BR0213843A (pt) | Derivado de quinazolina, processo para a preparação de um derivado de quinazolina, composição farmacêutica, e, uso de um derivado de quinazolina | |
| DE60003949D1 (de) | 5-aryl-1h-1,2,4 triazolverbindungen als cyclooxygenase -2 inhibitoren und dieseenthaltende pharmazeutische zusammensetzungen | |
| BR0209129A (pt) | Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos | |
| BRPI0410669A (pt) | inibidores de caspase e usos dos mesmo | |
| ATE542795T1 (de) | Benzylpiperazinderivate als motilin- rezeptorantagonisten | |
| BR0212435A (pt) | Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase | |
| MEP23008A (en) | Aminoalkylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same | |
| DK1456212T3 (da) | 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse | |
| DE60221425D1 (de) | Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase-inhibitoren | |
| NO20070980L (no) | Selekterte kondenserte heterocykler og anvendelser derav | |
| DK1355906T3 (da) | 2H-1-benzopyranderivater, fremgangsmåder til deres fremstilling og farmaceutiske sammensætninger indeholdende dem | |
| ATE419242T1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren |